share_log

VBI Vaccines Analyst Ratings

Benzinga Analyst Ratings ·  Nov 11, 2022 06:36
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/11/2022 236.7% Raymond James $5 → $2 Downgrades Strong Buy → Outperform
08/09/2022 741.75% Raymond James $6 → $5 Maintains Strong Buy
03/08/2022 910.1% Raymond James $9 → $6 Maintains Strong Buy
08/27/2020 1415.15% Raymond James $8 → $9 Upgrades Outperform → Strong Buy
07/22/2020 1246.8% Raymond James $3 → $8 Maintains Outperform
11/14/2019 405.05% Raymond James → $3 Initiates Coverage On → Outperform
01/16/2019 1415.15% Oppenheimer → $9 Initiates Coverage On → Outperform
07/27/2018 1920.2% BMO Capital $13 → $12 Maintains Outperform
11/15/2017 1751.85% BMO Capital → $11 Initiates Coverage On → Outperform

VBI Vaccines Questions & Answers

What is the target price for VBI Vaccines (VBIV)?

The latest price target for VBI Vaccines (NASDAQ: VBIV) was reported by Raymond James on November 11, 2022. The analyst firm set a price target for $2.00 expecting VBIV to rise to within 12 months (a possible 236.70% upside). 3 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for VBI Vaccines (VBIV)?

The latest analyst rating for VBI Vaccines (NASDAQ: VBIV) was provided by Raymond James, and VBI Vaccines downgraded their outperform rating.

When is the next analyst rating going to be posted or updated for VBI Vaccines (VBIV)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of VBI Vaccines, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for VBI Vaccines was filed on November 11, 2022 so you should expect the next rating to be made available sometime around November 11, 2023.

Is the Analyst Rating VBI Vaccines (VBIV) correct?

While ratings are subjective and will change, the latest VBI Vaccines (VBIV) rating was a downgraded with a price target of $5.00 to $2.00. The current price VBI Vaccines (VBIV) is trading at is $0.59, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment